#NASDAQ ACRS
-

Aclaris Therapeutics Stock Falls 13.5% After Phase 2 Eczema Setback
Aclaris Therapeutics shares slid in premarket trading after bosakitug missed both primary and secondary endpoints in a Phase 2 atopic…

Aclaris Therapeutics shares slid in premarket trading after bosakitug missed both primary and secondary endpoints in a Phase 2 atopic…